Filter by: patients
What is Tussionex Pennkinetic?

Tussionex® Pennkinetic® Extended-Release Suspension is a brand name for the combination of hydrocodone, an opioid analgesic and chlorpheniramine, an antihistamine used to treat runny or stuffy nose, sneezing, and cough caused by the common cold or flu.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Unrelenting cough 2 1 Efficacy_major
Churg Strauss Syndrome 1 0

See all 3 patients currently taking Tussionex Pennkinetic

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
1
None
0

Commonly reported side effects, conditions, and hospitalizations associated with Tussionex Pennkinetic

Knocks you out 1

Reported Dosages

  8mg-10mg/5mL as needed 8 mg-10 mg/5 mL daily
  1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Tussionex Pennkinetic (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped taking Tussionex Pennkinetic

Currently Taking Tussionex Pennkinetic

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Tussionex Pennkinetic

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Tussionex Pennkinetic

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Tussionex Pennkinetic

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

Cost of Tussionex Pennkinetic

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 12, 2012.